Topic Hub

Vyvanse — Regulatory History

4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.

4articles

31keywords mapped

2026-05-25latest review

Explore

Vyvanse — Regulatory History library

Showing 4 of 4 clinical reviews.

Questions2026-05-25

Vyvanse Compounding Legal Status: FDA Rules, DEA Restrictions, and What Patients Need to Know

A detailed look at the legal status of compounding lisdexamfetamine (Vyvanse), including FDA regulations under 503A/503B, DEA Schedule II restrictions, and state-level rules.

Read clinical review

Clinical Reviews2026-05-26

Vyvanse FDA Approval History: Every Regulatory Milestone from 2007 to Generic Entry

A complete timeline of Vyvanse (lisdexamfetamine) FDA approvals, label expansions, safety updates, and generic entry, with primary-source citations from Drugs@FDA and PubMed.

Read clinical review

Clinical Reviews2026-05-26

Vyvanse Global Regulatory Status: FDA Approval, International Scheduling, and Post-Market Surveillance

A comprehensive review of lisdexamfetamine (Vyvanse) regulatory status worldwide, including FDA approval history, EMA authorization, scheduling classifications, label updates, and ongoing safety monitoring.

Read clinical review

Clinical Reviews2026-05-26

Vyvanse Legal and Patent Challenges: FDA History, Litigation, and Generic Entry

A detailed review of Vyvanse (lisdexamfetamine) patent litigation, Hatch-Waxman challenges, FDA approval timeline, and the path to generic availability.

Read clinical review